![]()
|
|
||||||||
J. Biol. Chem., Vol. 281, Issue 26, 17751-17757, June 30, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-Catenin Phosphorylation and Ubiquitination in Colon Cancer Cells*





1
From the
Sealy Center for Cancer Cell Biology and Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas 77555 and the
Division of Neuroscience, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115
Most colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the
-catenin gene that stabilize
-catenin and activate
-catenin target genes, leading ultimately to cancer. The molecular mechanisms of APC function in
-catenin degradation are not completely known. APC binds
-catenin and is involved in the Axin complex, suggesting that APC regulates
-catenin phosphorylation. Some evidence also suggests that APC regulates
-catenin nuclear export. Here, we examine the effects of APC mutations on
-catenin phosphorylation, ubiquitination, and degradation in the colon cancer cell lines SW480, DLD-1, and HT29, each of which contains a different APC truncation. Although the current models suggest that
-catenin phosphorylation should be inhibited by APC mutations, we detected significant
-catenin phosphorylation in these cells. However,
-catenin ubiquitination and degradation were inhibited in SW480 but not in DLD-1 and HT29 cells. The ubiquitination of
-catenin in SW480 cells can be rescued by exogenous expression of APC. The APC domains required for
-catenin ubiquitination were analyzed. Our results suggest that APC regulates
-catenin phosphorylation and ubiquitination by distinct domains and by separate molecular mechanisms.
Received for publication, January 26, 2006 , and in revised form, April 24, 2006.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by a John Sealy Memorial Fund recruitment award and by Grant R21 CA112007 from the NCI, National Institutes of Health. To whom correspondence should be addressed. Tel.: 409-747-1909; Fax: 409-747-1938; E-mail: chliu{at}utmb.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
D. Romero, M. Iglesias, C. P.H. Vary, and M. Quintanilla Functional blockade of Smad4 leads to a decrease in {beta}-catenin levels and signaling activity in human pancreatic carcinoma cells Carcinogenesis, May 1, 2008; 29(5): 1070 - 1076. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Ramocki, H. R. Wilkins, S. T. Magness, J. G. Simmons, B. P. Scull, G. H. Lee, K. K. McNaughton, and P. K. Lund Insulin Receptor Substrate-1 Deficiency Promotes Apoptosis in the Putative Intestinal Crypt Stem Cell Region, Limits Apcmin/+ Tumors, and Regulates Sox9 Endocrinology, January 1, 2008; 149(1): 261 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kuroda, S. D. Rabkin, and R. L. Martuza Effective Treatment of Tumors with Strong {beta}-Catenin/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector. Cancer Res., October 15, 2006; 66(20): 10127 - 10135. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |